Stifel analyst Matthew Blackman initiated Cardiovascular Systems with a Buy rating and $45 price target, telling investors in a research note that he believes Cardiovascular Systems' shares are undervalued and sees upside as the company now more-consistently executes against an increasing number of near, intermediate, and longer-term growth-enhancing drivers. Following a challenging FY19, Blackman contends that growth should improve in FY19 back to double-digits, and says growth in FY20 could further accelerate to mid-teen rates due to "multiple" new product and geographic expansion opportunities.